Rosen PP - Search Results

1

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

Baselga J, Seidman AD, Rosen PP, Norton L. Baselga J, et al. Among authors: rosen pp. Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):43-8. Oncology (Williston Park). 1997. PMID: 9110342 Free article. Review.

2

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Baselga J, et al. Among authors: rosen pp. J Clin Oncol. 1996 Mar;14(3):737-44. doi: 10.1200/JCO.1996.14.3.737. J Clin Oncol. 1996. PMID: 8622019 Clinical Trial.

3

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Baselga J, et al. Among authors: rosen pp. Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83. Semin Oncol. 1999. PMID: 10482197 Clinical Trial.

4

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Rosen PP, et al. Cancer. 1995 Mar 15;75(6):1320-6. doi: 10.1002/1097-0142(19950315)75:6<1320::aid-cncr2820750614>3.0.co;2-c. Cancer. 1995. PMID: 7882282

5

Refining the origins of breast cancer.

Norton L, Rosen PP, Rosen N. Norton L, et al. Among authors: rosen pp, rosen n. Nat Med. 1995 Dec;1(12):1250-1. doi: 10.1038/nm1295-1250. Nat Med. 1995. PMID: 7489402 No abstract available.

6

Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.

Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP. Youngson BJ, et al. Among authors: rosen pp. Am J Surg Pathol. 1995 Dec;19(12):1354-8. doi: 10.1097/00000478-199512000-00002. Am J Surg Pathol. 1995. PMID: 7503357

7

p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Rosen PP, et al. J Clin Oncol. 1995 Apr;13(4):821-30. doi: 10.1200/JCO.1995.13.4.821. J Clin Oncol. 1995. PMID: 7707107

8

Immunophenotype of intraductal carcinoma.

Bose S, Lesser ML, Norton L, Rosen PP. Bose S, et al. Among authors: rosen pp. Arch Pathol Lab Med. 1996 Jan;120(1):81-5. Arch Pathol Lab Med. 1996. PMID: 8554451

9

BRCA-associated breast cancer: absence of a characteristic immunophenotype.

Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K. Robson M, et al. Among authors: rosen pp. Cancer Res. 1998 May 1;58(9):1839-42. Cancer Res. 1998. PMID: 9581822

10

Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.

Rosen PP, Groshen S, Kinne DW, Norton L. Rosen PP, et al. J Clin Oncol. 1993 Nov;11(11):2090-100. doi: 10.1200/JCO.1993.11.11.2090. J Clin Oncol. 1993. PMID: 8229123

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

281 results

Search Page

Filters